Premium
Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome
Author(s) -
Kofoed Peter Kristian,
Munch Inger Christine,
Larsen Michael
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.01612.x
Subject(s) - medicine , ranibizumab , ophthalmology , retinal , fluorescein angiography , ischemia , surgery , chemotherapy , bevacizumab
Acta Ophthalmol. 2010: 88: 808–810 Abstract. Purpose: To report the result of ranibizumab administration in an eye with ocular ischaemic syndrome. Methods: Fluorescein angiography, ocular pneumoplethysmography and retinal vessel calibre measurement. Results: An 85‐year‐old man with ocular ischaemic syndrome demonstrated vision loss, retinal vessel calibre constriction and profound retinal ischaemia after intravitreal ranibizumab. Conclusion: We advise against the use of intravitreal vascular endothelial growth factor inhibitors in eyes with ocular ischaemic syndrome.